Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

11:04 EDT 5th October 2015 | BioPortfolio

Drug Discovery News - Page: 4Twitter RSS

Read the latest Drug Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Drug Discovery.

Search or Follow Our Drug Discovery - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Drug Discovery - Page: 4 News.
You can also follow our Drug Discovery - Page: 4 news stories on Twitter: @DiscoveryDrug

Showing "drug drug discovery discovery" News Articles 76 to 100 of 24,000+

Sunday 4th October 2015

DARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush

DARA's Salesforce to Launch Oravig Into Oncology Market, While Marketing Partner, Mission Pharmacal, Launches Into the Primary Care Market; Over 28 Million Prescriptions Filled Annually for Oral Thrush in the U.S. RALEIGH, NC--(Marketwired - October 05, 2015) - DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare pro...

Nemus Bioscience Partners With Atheln to Accelerate Drug Development Pipelines

COSTA MESA, CA--(Marketwired - October 05, 2015) - Nemus Bioscience, Inc. (OTCQB: NMUS) has announced that it has signed a contract with Atheln, Inc., a California-based consulting group comprised of seasoned professionals skilled across the spectrum of drug development and product strategy, from chemistry/formulation to pre-clinical studies through NDA filing. Atheln will be focused on the develo...

Patheon to Highlight Flexible Capacity Solutions and Solubilization at CPhI/ICSE Worldwide 2015

DURHAM, NC--(Marketwired - October 05, 2015) - Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will be on site at the 26th Annual CPhI/ICSE Worldwide conference from , Oct. 13 - Oct. 15, in Madrid. Two noted Patheon experts will present at the Speaker's Corner on Wednesday, Oct. 14. At noon, Marshall Crew...

Global Drug Delivery in Cancer Market Study 2015 - Technologies, Markets and Companies Analysis

Dublin, Oct. 05, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/fdwm3x/drug_delivery_in) has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering.

Flamel Ireland Limited Licenses LiquiTime(R) Technology to Perrigo for U.S. Over-the-Counter Market

LYON, FRANCE -- (Marketwired) -- 10/05/15 -- Flamel Technologies (NASDAQ: FLML) announced today that the Company's Irish subsidiary, Flamel Ireland Limited, has licensed exclusive U.S. rights to the LiquiTime® drug delivery platform to Perrigo's Irish subsidiary, Elan Pharma International Limited, for the U.S. Over-the-Counter (OTC) drug market. LiquiTime® is Flamel's drug delivery platform for...

UPDATE 5-After five years of negotiations, Pacific trade talks near deal

* Australia's Robb says TPP partners reviewing biologic drug terms (Adds quote from Australia trade minister Robb)

Drug Used to Treat Cancer Appears to Sharpen Memory

Rutgers research provides clues to keeping brain cells alive in those with Alzheimer’s

Sandoz's BLA for biosimilar etanercept gets FDA acceptance

The US Food and Drug Administration (FDA) has accepted Novartis company Sandoz's biologics licence application (BLA) under the 351(k) pathway for etanercept, a biosimilar to Amgen's Enbrel drug.

Novel Parkinson’s Therapy Moves Ahead Through Korea Deal

South Korean researchers have taken a step forward in developing a disease-modifying treatment for Parkinson's disease. Kainos Medicine has licensed in an innovative candidate for the now incurable disease, KR-33493, which is set for clinical trials ...

Update on Need for Facilities to Review Procedures for Disinfecting, Sterilizing Reusable Devices

As a follow-up to an alert issued on Sept. 11, 2015, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are providing an update to rescind the following recommendation: "If healthcare facilities contract maintenance and repair of these devices to third-party vendors, healthcare facilities should verify

Trio win Nobel Medicine Prize for parasite therapies

A trio of scientists earned the 2015 Nobel Prize for Medicine on Monday for unlocking revolutionary treatments for malaria and r

Partnerships for medicines access and drug pricing feature at European Health Forum

Speaking at European Health Forum Gastein, which took place in Austria last week, European Commissioner…

Australia sees way to resolve TPP drug dispute with United States

SYDNEY, Oct 4 (Reuters) - Australia sees a way forward to resolve a dispute with the United States over next-generation medicines that is stalling Pacific trade talks but "splitting it down the middle" on patent protections will not be the answer, Au...

EMD Serono Announces Grant for Growth Innovation at ESPE in Barcelona

DARMSTADT, Germany, Oct. 4, 2015 /PRNewswire/ -- EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced the recipients of the Grant for Growth Innovation (GGI) for 2015. The awards were handed over during the official award ceremony yesterday evening at the 54th European Society for Paediatric Endocrinology (ESPE) Meeting currently taking place in Barcel...

Phase 2 Data from Spinal Muscular Atrophy Program to be Presented at the 20th International Annual Congress of the World Muscle Society

BRIGHTON, United Kingdom, Oct. 4, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that clinical data from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) were presented at the 20th International Congress of the World Muscle Society (WMS) in Brighton, U.K. Results from the first cohort of patients enrolled in the...

Myeloma Treatment Options Continue to Emerge (CME/CE)

(MedPage Today) -- Several drug classes show promise for better outcomes

Researchers Say Mesothelioma Vaccine Looks Promising So Far, According to Surviving Mesothelioma

Scientists studying a new vaccine for mesothelioma have released some encouraging early results from a clinical trial. Raleigh, NC (PRWEB) October 04, 2015 Doctors say 94% of mesothelioma patients who have received the new immunotherapy drug CRS-207 along with chemotherapy as part of an ongoing clinical trial have responded to the treatment. Surviving Mesothelioma has the full story. Click here t...

Cambridge Research Biochemicals signs licensing deal with The Scripps Research Institute for ‘click’ chemistry

Leading research peptide manufacturer Cambridge Research Biochemicals (CRB) announced today that it has signed a non-exclusive license with The Scripps Research Institute (TSRI) to add click chemistry services, namely the “click” labellin...

OBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan

TAIPEI, Oct. 4, 2015 /PRNewswire/ -- OBI Pharma, Inc. (TPex: 4174) today announced an agreement with MSD, known as Merck in the United States and Canada, through a subsidiary transferring exclusive rights to develop and commercialize Dificid® (fidaxomicin) in Taiwan to MSD. This agreement will enable the launch of Dificid® in Taiwan utilizing MSD's extensive market expertise ...

Saturday 3rd October 2015

Avita Medical Announces U.S. FDA Doubles Patient Numbers Permitted for Compassionate Use of ReCell(R)

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwired) -- 10/04/15 -- Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced approval from the U.S. Food and Drug Administration (FDA) for the expansion of its Compassionate Use Investigational Device Exemption (IDE) program for ReCell®. The ID...

Amicus Therapeutics tanks on news of delay for migalastat approval

Amicus Therapeutics on Friday revealed that the US Food and Drug Administration is calling for additional…

FDA approves expanded use of Keytruda, for advanced NSCLC

The US Food and Drug Administration on Friday granted accelerated approval for pharma giant Merck & Co’s…

FDA approves Gilead's Letairis with tadalafil for PAH

Gilead Sciences said on Friday that US Food and Drug Administration has approved the use of its Letairis…

FDA Approves Keytruda for Metastatic Non-Small Cell Lung Cancer

The US Food and Drug Administration (FDA) today announced that it has granted accelerated approval for Merck’s anti-PD-1 agent pembrolizumab (Keytruda) for treating patients with refractory metastatic non-small cell lung cancer (NSCLC) tumors that express programmed cell death protein ligand 1 (PD-L1).

Regulate Gene Expression with Altogen Labs RNAi Technology

Austin, TX, October 03, 2015 --(PR.com)-- Ribonucleic Acid or RNA is a molecule critical to biology because it is behind the coding, regulation and expression of genes. With the RNA Interference or RNAi technology service offered by Altogen Labs it is possible to effectively regulate gene expression. Moreover, Altogen Labs has developed methods to prevent siRNA degradation in serum (including bot...


News Quicklinks